ClinicalTrials.gg
CompletedNCT03625323TACTI-002Updated Apr 22, 2026Results posted

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

A Phase 2 interventional study of eftilagimod alpha and pembrolizumab (KEYTRUDA®) in NSCLC and HNSCC, sponsored by Immutep S.A.S.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Immutep S.A.S. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
146th of 993
187 · median 41
Started
2019
with 70 others
Phase 2
359 of 1,099
58 open now
Registered
556th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 146th largest by enrollment of the 993 interventional ones that give a count, is one of 71 that started in 2019, is one of 359 in phase 2, and was the 556th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.

Read the detailed description

Up to 187 patients will be recruited in the TACTI-002 (Two ACTive Immunotherapies) Phase II study which will take place across approximately 22 study centres in the U.S., Europe and Australia. It will evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in patients with advanced or metastatic non-small cell lung carcinoma or head and neck carcinoma. It will be a Simon's two-stage, non-comparative, open-label, single-arm, multicentre clinical study. Patients participating in the trial will be given the combination treatment for 12 months using a 30 mg s.c. eftilagimod alpha dosing every 2 or 3 weeks.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Part A (, PD-X naïve NSCLC): - or cytologically-confirmed diagnosis of non-small cell lung carcinoma stage IIIB not amenable to curative treatment or stage IV not amenable to EGFR/ALK based therapy, treatment naïve for systemic therapy given for advanced/ disease (previous palliative radiotherapy for advanced/metastatic disease acceptable)

    Part B (2nd line, PD-X NSCLC): histologically- or cytologically-confirmed diagnosis of NSCLC after failure of first-line treatment (for metastatic disease) with at least 2 cycles of any /PD-L1 containing based therapy (e.g. nivolumab, pembrolizumab, avelumab, durvalumab, etc.) alone, or in combination with any other immunotherapeutic or chemotherapy given as part of first-line treatment.

    Part C (2nd line PD-X naive HNSCC): Histologically- or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies after failure of prior platinum-based therapy.

  2. Submission of formalin-fixed diagnostic tumor tissue
  3. performance status 0-1.
  4. Expected survival > 3 months.

Main Exclusion Criteria:

  1. For part A (1st line, PD-X naïve NSCLC):

    • The NSCLC can be treated with curative intent with either surgical resection and/or chemoradiation and/or radiation.
    • Has received systemic therapy for the treatment of their stage IV NSCLC. Completion of treatment with chemotherapy and/or radiation as part of /adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease.
    • EGFR-sensitizing mutation and/or is EML4 gene/ ALK gene fusion positive (ALK translocation).
    • Lung radiation therapy that is >30Gy within 6 months of the first dose of trial treatment.

    For Part B (2nd line, PD-X refractory NSCLC):

    • Symptomatic ascites or pleural effusion.
    • > 1 line of chemotherapy for metastatic disease.
    • Lung radiation therapy that is >30Gy within 6 months of the first dose of trial treatment.

    For Part C (2nd line PD-X naive HNSCC):

    • Disease is suitable for local therapy administered with curative intent.
    • Previously treated with > 1 systemic regimens for recurrent and/or metastatic disease.
  2. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) (Part A and C only)
  3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE (Part B only)
  4. Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery, another systemic cancer therapy or has participated in a study of an agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.

    Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy, alopecia and elevated transaminases in case of liver metastases may be eligible. If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

  5. Known active central nervous system metastasis and/or carcinomatous meningitis. Patients with previously treated may participate provided they are radiologically stable: i.e. without evidence of progression documented by repeat imaging performed after therapy completed for CNS metastasis and with at least 4 weeks difference, clinically stable and without requirement for treatment for at least 14 days prior to cycle 1 day 1.
  6. Receives continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other medications within 7 days prior to cycle 1 day 1. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    1st line NSCLC

    eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9). pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.

    Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)

  • Experimental
    2nd line NSCLC

    eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9). pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.

    Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)

  • Experimental
    HNSCC

    eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9). pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks.

    Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed)

    ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months

  2. Evaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed)

    ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months

Secondary outcomes

  1. Duration of (Serious) Adverse Events

    Time frame: up to 27 months

  2. Frequency of (Serious) Adverse Events

    Time frame: up to 27 months

  3. Severity of (Serious) Adverse Events

    Time frame: up to 27 months

  4. Time to Responses According to iRECIST and RECIST 1.1

    Time frame: up to 68 months

  5. Duration of Responses According to iRECIST and RECIST 1.1

    Time frame: up to 68 months

  6. Response Rate According to RECIST 1.1

    Time frame: up to 68 months

  7. Disease Control Rate According to iRECIST and RECIST 1.1

    Time frame: up to 68 months

  8. Progression Free Survival (PFS)

    Time frame: up to 68 months

  9. Overall Survival (OS)

    Time frame: up to 68 months

  10. Occurrence of Eftilagimod Alpha-specific Antibodies (ADA)

    Time frame: up to 24 month

  11. Plasma Concentration Time Profile of Eftilagimod Alpha

    Time frame: up to 24 month

07

Results

Posted Dec 18, 2024

Participant flow

The first ICF for the study was signed on February 21, 2019. Recruitment ended on November 30, 2021. 18 sites in 6 countries. Number of sites per country: Australia (2), Poland (1), Spain (8), UK (3), Ukraine (2) and US (2).

Participant flow — Overall Study
Milestone1st Line NSCLC2nd Line NSCLC2nd Line HNSCC
Started1143637
Completed2224
Not completed923433

Outcome measures

PrimaryEvaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed)

ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months
Reported as:
Count of participants · Participants
Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed)
Participants1st Line NSCLC2nd Line NSCLCHNSCC
Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed)46311
PrimaryEvaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed)

ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months
Reported as:
Count of participants · Participants
Evaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed)
Participants1st Line NSCLC2nd Line NSCLCHNSCC
Evaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed)40310
SecondaryDuration of (Serious) Adverse Events
Time frame:
up to 27 months

Results for this outcome have not been posted.

SecondaryFrequency of (Serious) Adverse Events
Time frame:
up to 27 months

Results for this outcome have not been posted.

SecondarySeverity of (Serious) Adverse Events
Time frame:
up to 27 months

Results for this outcome have not been posted.

SecondaryTime to Responses According to iRECIST and RECIST 1.1
Time frame:
up to 68 months

Results for this outcome have not been posted.

SecondaryDuration of Responses According to iRECIST and RECIST 1.1
Time frame:
up to 68 months

Results for this outcome have not been posted.

SecondaryResponse Rate According to RECIST 1.1
Time frame:
up to 68 months

Results for this outcome have not been posted.

SecondaryDisease Control Rate According to iRECIST and RECIST 1.1
Time frame:
up to 68 months

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS)
Time frame:
up to 68 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
up to 68 months

Results for this outcome have not been posted.

SecondaryOccurrence of Eftilagimod Alpha-specific Antibodies (ADA)
Time frame:
up to 24 month

Results for this outcome have not been posted.

SecondaryPlasma Concentration Time Profile of Eftilagimod Alpha
Time frame:
up to 24 month

Results for this outcome have not been posted.

Adverse events

Collected over Up to 27 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1st Line NSCLC84/114 (73.7%)54/114 (47.4%)114/114 (100%)
2nd Line NSCLC30/36 (83.3%)9/36 (25%)35/36 (97.2%)
2nd Line HNSCC31/37 (83.8%)20/37 (54.1%)36/37 (97.3%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
Event1st Line NSCLC2nd Line NSCLC2nd Line HNSCC
DyspneaRespiratory, thoracic and mediastinal disorders8/1140/360/37
Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1141/362/37
Urinary tract infectionInfections and infestations0/1140/362/37
HypercalcemiaMetabolism and nutrition disorders0/1140/362/37
SyncopeNervous system disorders0/1140/362/37
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1140/362/37
PneumonitisRespiratory, thoracic and mediastinal disorders4/1140/361/37
HemoptysisRespiratory, thoracic and mediastinal disorders4/1140/360/37
Lower respiratory tract infectionInfections and infestations2/1141/361/37
PneumoniaInfections and infestations3/1141/361/37
Most frequent other events
Showing 10 of 80
Most frequent other events
Event1st Line NSCLC2nd Line NSCLC2nd Line HNSCC
DyspnoeaRespiratory, thoracic and mediastinal disorders39/11413/363/37
Decreased appetiteMetabolism and nutrition disorders30/11413/364/37
AstheniaGeneral disorders39/1148/368/37
CoughRespiratory, thoracic and mediastinal disorders34/11411/367/37
AnaemiaBlood and lymphatic system disorders28/1141/367/37
PruritusSkin and subcutaneous tissue disorders27/1145/364/37
FatigueGeneral disorders26/1148/366/37
ArthralgiaMusculoskeletal and connective tissue disorders19/1147/364/37
Weight decreasedInvestigations6/1146/367/37
HypothyroidismEndocrine disorders11/1141/367/37

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1st Line NSCLC2nd Line NSCLCHNSCCTotal
<=18 years0000
Between 18 and 65 years39152074
>=65 years752117113
Age, Continuous
Age, Continuous(Years)1st Line NSCLC2nd Line NSCLCHNSCCTotal
Median67 (44 to 85)67 (46 to 84)63 (48 to 84)67 (44 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)1st Line NSCLC2nd Line NSCLCHNSCCTotal
Female3014448
Male842233139
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1st Line NSCLC2nd Line NSCLCHNSCCTotal
American Indian or Alaska Native0000
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American2204
White1093435178
More than one race0000
Unknown or Not Reported2013
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1st Line NSCLC2nd Line NSCLCHNSCCTotal
Hispanic or Latino54110
Not Hispanic or Latino1093236177
Unknown or Not Reported0000
Smoking history
Smoking history(Participants)1st Line NSCLC2nd Line NSCLCHNSCCTotal
Non-smoker65516
Ex- or current smoker1083132171
08

Study locations

1 site
  • Oncology Consultants
    Huston, Texas 77030, United States
09

References and documents

Publications

  • Krebs MG, Forster M, Majem M, Peguero J, Iams W, Clay T, Roxburgh P, Doger B, Bajaj P, Barba A, Perera S, Mueller C, Triebel F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. JTO Clin Res Rep. 2024 Aug 30;5(11):100725. doi: 10.1016/j.jtocrr.2024.100725. eCollection 2024 Nov. PubMed 39403626 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jun 2022, 39 months.

Results were first posted in Dec 2024, 2 years 6 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 39 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2018
First posted
Aug 10, 2018
StartActual
Feb 21, 2019
Primary completionActual
Jun 2, 2022
CompletionActual
Nov 25, 2024
Results first posted
Dec 18, 2024
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03625323
Lead sponsor
Immutep S.A.S.
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Feb 21, 2019
Primary completion
Jun 2, 2022
Completion
Nov 25, 2024
Results posted
Dec 18, 2024
Last update
Apr 22, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etilagimod alpha

Start the discussion